On Feb 8, 2019 EXICURE INC (OTCMKTS:XCUR) Shorts Strengthened By 4.34%

EXICURE INC (OTCMKTS:XCUR) recorded an increase of 4.34% in shares shorted. FINRA announced in February XCUR’s total 52,900 shares shorted. The up change of 4.34% from 50,700 shares was reported. With Average volume 58,600, XCUR’s previous position will take 1 days to recover.

At traded at $2.94 lastly.Since February 8, 2018 it’s 0.00% down thus . The stock the S&P 500 by 0.00%.

Exicure, Inc., a clinical stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid technology.The firm is worth $130.41 million. The company's three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an antisense SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA containing tumor necrosis factor antisense oligonucleotides.Last it reported negative earnings. It is also developing SNAs that target IL-4RA mRNA for the treatment of atopic dermatitis; and marketing dupilumab, a human monoclonal antibody for treating moderate to severe atopic dermatitis in the United States.

There’s an important Exicure, Inc. (OTCMKTS:XCUR) news posted by Seekingalpha.com. It’s an item titled: “Exicure, Inc. announces expected closing of ~$22M private placement offering – Seeking Alpha” on August 22, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.